Ritter Pharma engages AGP to explore strategic alternatives

Ritter Pharmaceuticals (NASDAQ:RTTR) has engaged Alliance Global Partners as a financial advisor to help the company evaluate strategic alternatives. 

The company is considering a variety of options, including an acquisition, merger, reverse merger, other business combination, sale of assets, licensing or other strategic transactions. 

On Sept. 12, the company reported that its Phase 3 clinical trial of RP-G28 for the treatment of lactose intolerance failed to demonstrate statistically significant symptom improvements compared to placebo.


Sign up to our weekly BioTuesdays newsletter.